1 / 19

Invasive Candidiasis: Part 1

Invasive Candidiasis: Part 1. Aetiology, Pathogenesis & Clinical manifestation. Arnaldo Lopes Colombo, MD Federal University of São Paulo, Brazil. Intended Learning Outcomes. To recognise the spectrum of diseases caused by Candida. To appreciate the different forms of invasive candidiasis.

bleau
Télécharger la présentation

Invasive Candidiasis: Part 1

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Invasive Candidiasis: Part 1 Aetiology, Pathogenesis & Clinical manifestation Arnaldo Lopes Colombo, MD Federal University of São Paulo, Brazil

  2. Intended Learning Outcomes To recognise the spectrum of diseases caused by Candida To appreciate the different forms of invasive candidiasis To be aware of the risk factors of candidaemia To understand the pathogenesis in invasive candidiasis

  3. Spectrum of Candida diseases Non-haematogenous infections • Superficial infections • Cutaneous candidiasis • Oropharyngeal candidiasis • Vaginitis • Deep-seated infections • Oesophageal candidiasis • Tracheitis/bronchitis • Intra-abdominal/candida peritonitis • CAPD peritonitis • Cystitis Eggimann et al. Lancet Infect Dis 2003; 3: 685-702 Haematogenous infections Candidaemia Hepatosplenic candidiasis (leukaemia) Endophthalmitis Vascular-access-related infection Septic thrombophlebitis Arthritis Osteomyelitis Spondylodiscitis Meningitis and brain abscess Pyelonephritis and fungal balls Pulmonary candidiasis (rare)

  4. Invasive candidiasis Kullberg & Arendrup. N Engl J Med2015;373:1445-56. Invasive candidiasis = candidaemia + deep-seated tissue candidiasis Candidaemia is the most commonly diagnosed form of invasive candidiasis Mortality attributable to invasive candidiasis is as high as 40%, even with antifungal therapy C. albicans is the most common Candida spp., however, there is a global shift in favour of non-albicans species

  5. Manifestations of invasive candidiasis Deep-seated candidiasis Candidaemia and deep-seated candidiasis Candidaemia in the absence of deep-seated candidiasis Clancy & Nguyen: Clin Infect Dis. 2013; 56: 1284-92. Kullberg & Arendrup. N Engl J Med2015;373:1445-56.

  6. Early diagnosis of candidemia is challenging 2 Why should we care about candidemia? Increasing incidence of candidemiaworldwide1 High number of patients at risk No specific signs and symptoms Culture-based methods are insensitive and time consuming Antigens tests and molecular methods are quite expensive for lower income countries High mortality rate Fungal Infections in France Population-based survey 1-Bitar D et al, Emerging Infectious Diseases. 2014;20:1149-55 2 - Colombo AL, et al. Lancet InfectDis2017;17(11):e344-e356.

  7. Candidemia: Shift in burden from neonates to adults in developed countries A comparison of annual incidence rates per 100 000 persons in USA: 1992–1993 vs 2008–2011 Cleveland AA, et al. Clin Infect Dis. 2012;55:1352-61.

  8. HIGH PREVALENCE of candidemia in pediatric patients in Latin America !! Nucci M, Colombo Al et al. PLoS One. 2013;8:e59373. Cleveland AA, et al. Clin Infect Dis. 2012;55:1352-61.

  9. Neonatal candidiasis • Neonatal candidemia • Increased length of hospital stay and mortality • Increased health care costs • Associate neuro-developmental impairment • High frequency of associated meningitis • Assume CNS infection in all neonates (~40%) • C. albicans and C. parapsillosis in 80-90% of the cases • Earliest sign is usually increased respiratory requirement - symptoms are usually non-specific or subtle BSI: Blood Stream Infection. NICU: Neonatal Intensive Care Unit

  10. Mortality rate of candidemia in ICU BRAZIL-1-Girão E et al, Med Mycol 2008; BRAZIL-2 -Colombo et al Intensive Care Med 2014 FRANCE- Lortholary O et al, Intensive Care Med, 2014; EPIC II- Kett DH et al Crit Care Med, 2011; ITALY- Montagna MT et al, Infection , 2013

  11. Candidemia: main factors associated with outcome Age APACHE II score Co-morbidities Species of Candida Timing and choice of antifungal drug Candins appears to be better choice Management of the infectious focus Catheter removal, drainage of abscess Morrell M, et al. Antimicrob Agents Chemother. 2005;49:3640-5. Andes DR, et al. Clin Infect Dis. 2012;54:1110-22. Kollef M, et al. Clin Infect Dis. 2012;54:1739-46.

  12. Causative Candida species Considerable geographical, centre-to-centre and unit-to-unit variability At least 15 distinct spp. can cause human disease Most virulent • C. albicans (~50% or more) • C. tropicalis Less virulent • C. parapsillosis complex • C. krusei Less frequent species (<5%) • C. dubliniensis • C. lusitaniae • C. kefyr • C. guilliermondii Kullberg & Arendrup. N Engl J Med 2015;373:1445-56.

  13. Pathogenesis Candida spp. are colonisers and normal flora of human gut, skin and genitourinary tract Invasion results from a combination of increased fungal load and alteration of external barriers (skin and mucous membrane) Candida spp. adhere to body surfaces as well as devices (catheters, prosthetic valves etc.) forming biofilms Biofilm formation leads to upregulation of azole-resistance mechanisms and development of persister cells which have higher levels of antifungal resistance Eggimann et al. Lancet Infect Dis 2003; 3: 685-702

  14. Risk factors for invasive candidiasis Cleveland et al. PLoS ONE 2015; 10:e0120452. Colombo AL, et al. Lancet InfectDis 2017;17(11):e344-e356; • Critical illness: Long-term ICU stay • ~50% of episodes of candidaemia • Haemodialysis • Anti-cancer chemotherapy • Candida colonisation • Abdominal surgery: repeated laparotomies & anastomotic leakage

  15. Risk conditions for candidemia in ICU patients:They are all present in a substantial number of patients who will not develop candidemia! CANDIDEMIA!!! Risk of candidemia High colonization Low colonization Surgery, dialysis, steroids, total parenteral nutrition, pancreatitis, GI mucosal disruption, other Antibiotics + catheter Days after ICU admission 1. Colombo AL, et al. Lancet Infect Dis 2017;17(11):e344-e356;2. Colombo AL, et al. Intensive Care Med 2014;40(10):1489-98. GI: gastrointestinal; ICU: intensive care unit.

  16. Clinical features Systemic Inflammatory Response Syndrome (SIRS) • ≥ 2 of:- • Fever >380C or <360C • Tachycardia >90 beats/min • Tachypnoea >20 breaths/min • WBC* count >12,00 or <4,000 or >10% band neutrophils • Sepsis = SIRS + probable or confirmed infection *WBC=White blood cell counts Eggimann et al. Lancet Infect Dis 2003; 3: 685-702 • Early clinical manifestations are non-specific • Basically those of sepsis of any cause (bacteria, viruses or fungi) • No clinical sign or symptom is specific for candidaemia • Positive fundoscopic examination for Candida ophthalmitis is suggestive of candidaemia • Candidaendophthalmitis occurs in 3.7-25% of candidamia

  17. Manifestations of invasive candidiasis • Infections arise from an earlier or undiagnosed candidaemia or from direct inoculation into a sterile site • May remain localised, spread to contiguous site or lead to secondary candidaemia Clancy & Nguyen. Clin Infect Dis 2013; 56: 1284-92. Kullberg & Arendrup. N Engl J Med2015;373:1445-56. Candidaemia (most common) • Blood culture isolation of Candida spp. Deep-seated candidiasis (Blood culture negative) • Chronic disseminated candidiasis • Hepato-splenic candidiasis • Other deep-seated infections • Bones • Muscles • Joints • Eyes • CNS • Intra-abdominal/peritonitis

  18. Summary Candidaemia, the most common form of invasive candidiasis Increasing number of patients at risk worldwide Invasive candidiasis results from a combination of increased fungal load and alteration of epithelial barriers Early clinical manifestations are non-specific Mortality rate ranges between 30-75%, even with antifungal treatment

  19. END

More Related